ArticleFrontiers in pharmacology2021
Surface Engineering of
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 17 citations in OpenAlex.
- Review
- ADA2-Functionalized OMVs Remodel the Tumor Microenvironment in Pancreatic Cancer.Pharmaceutics · 2026Article
- Recent Progress in Exosome-Derived Nanocarriers for Breast Cancer Therapy: Advances, Translational Barriers, and Scale-Up Considerations.Pharmaceutical research · 2026Review
- Frontiers in bacterial outer membrane vesicles: From basic characteristics to cancer therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- Bacterial outer membrane vesicles: a smart platform for biomedical applications.Cell communication and signaling : CCS · 2026Review
- Advances in microbial extracellular vesicles: synthetic biology platforms and medical applications.Extracellular vesicles and circulating nucleic acids · 2026Review
- Outer membrane vesicles as a versatile nanoplatform for advanced vaccine development and immunotherapy.Frontiers in immunology · 2026Review
- Innovative Strategies in Oncology: Bacterial Membrane Vesicle-Based Drug Delivery Systems for Cancer Diagnosis and Therapy.Pharmaceutics · 2025Review
- Recent knowledge on squamous cell carcinoma of the oral cavity: Contributing factors, underlying molecular pathways, and current attitudes in the therapeutic approaches.International journal of molecular and cellular medicine · 2025Review
- The two coin sides of bacterial extracellular membrane nanovesicles: atherosclerosis trigger or remedy.Discover nano · 2024Review
- A molecular toolkit for heterologous protein secretion across Bacteroides species.Nature communications · 2024Article
- Harnessing exosomes as a platform for drug delivery in breast cancer: A systematic review forMolecular therapy. Oncology · 2024Review
- Synergistic vesicle-vector systems for targeted delivery.Journal of nanobiotechnology · 2024Review
- Identifying potential ligand molecules EGFR mediated TNBC targeting the kinase domain-identification of customized drugs throughResearch in pharmaceutical sciences · 2023Article
- Bacterial Membrane Vesicles as Smart Drug Delivery and Carrier Systems: A New Nanosystems Tool for Current Anticancer and Antimicrobial Therapy.Pharmaceutics · 2023Review
- In silico approach to probe the binding affinity between OMVs harboring the ZJournal of molecular modeling · 2022Article
- Bacterial extracellular vesicles-based therapeutic strategies for bone and soft tissue tumors therapy.Theranostics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial outer membrane vesicles (OMVs) have recently drawn a great deal of attention due to their therapeutic efficiency and ability to target specific cells. In the present study, we sought to probe engineered OMVs as novel and promising carriers to target breast cancer cells. Following the fusion of the affi
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.